Survival 12 years after randomization to streptokinase: The influence of thrombolysis in myocardial infarction flow at three to four weeks

Journal of the American College of Cardiology

Volumn 34, Issue 1, 1999, Pages 62-69

  French, John K ^a   Hyde, Thomas A ^a   Patel, Hitesh ^a   Amos, David J ^a   McLaughlin, Stephanie C ^a   Webber, Bruce J ^a   White, Harvey D ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PLACEBO; PROPRANOLOL; STREPTOKINASE;

ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; AGED; CORONARY VESSELS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; REGIONAL BLOOD FLOW; STREPTOKINASE; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; VENTRICULAR FUNCTION;

EID: 0033165689     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00166-7     Document Type: Article

References (38)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) . Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1:1986;397-402.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction ISIS-2 . Lancet. 2:1988;349-360.
3. White H.D., Norris R.M., Brown M.A., et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 317:1987;850-855.
4. French J.K., Hyde T.A., White H.D. Left ventricular function following thrombolytic therapy for myocardial infarction. J Interven Cardiol. 11:1998;9-18.
5. GUSTO Angiographic Investigators . The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction (published erratum appears in N Engl J Med 1994;330:516). N Engl J Med. 329:1993;1615-1622.
6. Smalling R.W., Bode C., Kalbfleisch J., et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 91:1995;2725-2732.
7. Bode C., Smalling R.W., Berg G., et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 94:1996;891-898.
8. White H.D., Aylward P.E., Frey M.J., et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 96:1997;2155-2161.
9. Chesebro J.H., Knatterud G., Roberts R., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge . Circulation. 76:1987;142-154.
10. White H.D. GISSI-2 and the heparin controversy. Lancet. 336:1990;297-298.
11. Simes R.J., Topol E.J., Holmes D.R. Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion importance of early and complete infarct artery reperfusion . Circulation. 91:1995;1923-1928.
12. Lenderink T., Simoons M.L., van Es G.-A., et al. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation. 92:1995;1110-1116.
13. ISIS Collaborative Group , Baigent C., Collins R. ISIS-2 4-year mortality follow-up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction (abstr) . Circulation. 88:1993;I-291.
14. Cerqueira M.D., Maynard C., Ritchie J.L., Davis K.B., Kennedy J.W. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction Trials. J Am Coll Cardiol. 20:1992;1452-1459.
15. White H.D., Cross D.B., Elliott J.M., Norris R.M., Yee T.W. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation. 89:1994;61-67.
16. French J.K., Williams B.F., Hart H.H., et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med J. 312:1996;1637-1641.
17. Whitlock R.M.L., Bass N.M. Left ventricular volume estimation by single-plane right anterior oblique cineangiocardiography. Proceedings of the Biological Engineering Society 20th Anniversary International Conference on Recent Advances in Biomedical Engineering. 1980;177-178 Biological Engineering Society, London.
18. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count a quantitative method of assessing coronary artery flow . Circulation. 93:1996;879-888.
19. Principal Investigators of CASS and Their Associates . The National Heart, Lung, and Blood Institute Coronary Artery Surgery Study (CASS) a multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease, and a registry of consecutive patients undergoing coronary angiography . Circulation. 63:1981;I-1-I-81.
20. Brandt P.W.T., Partridge J.B., Wattie W.J. Coronary arteriography method of presentation of the arteriogram and a scoring system . Clin Radiol. 28:1977;361-365.
21. LIPID Study Group . Design features and baseline characteristics of the LIPID (Long-Term Intervention With Pravastatin in Ischemic Disease) Study a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris . Am J Cardiol. 76:1995;474-479.
22. White H.D., Rivers J.T., Maslowski A.H., et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med. 320:1989;817-821.
23. Simoons M.L., Vos J., Tijssen J.G.P., et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands . J Am Coll Cardiol. 14:1989;1609-1615.
24. Baigent C., Collins R., Appleby P., et al. ISIS-2 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither . Br Med J. 316:1998;1337-1343.
25. GISSI Investigators , Franzosi M.G., Santoro E., De Vita C., et al. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 Study . Circulation. 98:1998;2659-2665.
26. Maas ACP, van Domburg RT, Deckers JW, et al. Sustained benefit at 10-14 years follow-up after thrombolytic therapy in myocardial infarction. Eur Heart J 1999 (in press).
27. Ross A.M., Coyne K.S., Moreyra E., et al. Extended mortality benefit of early postinfarction reperfusion. Circulation. 97:1998;1549-1556.
28. De Wood M.A., Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 303:1980;897-902.
29. Roux S., Christeller S., Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis a meta-analysis . J Am Coll Cardiol. 19:1992;671-677.
30. White H.D., Norris R.M., Brown M.A., Brandt P.W.T., Whitlock R.M.L., Wild C.J. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 76:1987;44-51.
31. Migrino R.Q., Young J.B., Ellis S.G., et al. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. Circulation. 96:1997;116-121.
32. White H.D. Should all occluded infarct-related arteries be opened? (editorial). Eur Heart J. 18:1997;1207-1209.
33. Villella A., Maggioni A.P., Villella M., et al. Prognostic significance of maximal exercise testing after myocardial infarction treated with thrombolytic agents: the GISSI-2 data-base. Gruppo Italiano per lo Studio della Sopravvivenza Nell'Infarto. Lancet. 346:1995;523-529.
34. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
35. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators . A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
36. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 143:1996;1-13.
37. van der Meer J., Hillege H.L., Kootstra G.J., et al. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants . Lancet. 342:1993;257-264.
38. Coumadin Aspirin Reinfarction Study (CARS) Investigators . Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet. 350:1997;389-396.